カテゴリ： GlobalData, アイルランド, 企業調査

Jazz Pharmaceuticals Plc (JAZZ)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10076
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：95
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アイルランド
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem, sodium oxybate oral solution, for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze, an asparagine specific enzyme, for acute lymphoblastic leukemia; Prialt, ziconotide, for severe chronic pain in patients who are intolerant or refractory to other treatments and FazaClo orally disintegrating clozapine tablets indicated for the treatment of resistant schizophrenia. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals Plc (JAZZ) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
JAZZ Pharma Acquires Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million 16
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 17
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million 19
Venture Financing 20
Arrivo BioVentures Raises USD49 Million in Venture Financing 20
Alize Pharma Raises USD1.9 Million in Venture Financing 21
Alize Pharma Raises USD6.4 Million in Series A Financing 22
Celator Pharma Raises US$39 Million In Venture Financing 23
Celator Pharma Raises USD4.1 Million in Venture Financing 24
Alize Pharma Raises US$4 Million In Venture Financing 25
Partnerships 26
Jazz Pharma and MD Anderson Cancer Center Enter into Agreement 26
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 27
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 28
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 29
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 30
Merger 31
Jazz Pharma Merges With Azur Pharma In All Stock Transaction 31
Licensing Agreements 33
Jazz Pharma Enters into License Agreement with XL-protein 33
Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 34
Jazz Pharma Amends Licensing Agreement with Pfenex 35
Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 37
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 38
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 40
Equity Offering 41
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 41
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 43
Debt Offering 45
Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 45
Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 46
Asset Transactions 47
TerSera Therapeutics to Acquire Prialt from Jazz Pharma for USD80 Million 47
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 48
Aytu BioScience Acquires ProstaScint from Jazz Pharma 49
Essex Bidco Acquires Assets from Jazz Pharma 50
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 52
Meda Completes Acquisition Of Women’s Health Business From Jazz Pharma For US$95 Million 53
Acquisition 55
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 55
Jazz Pharma Acquires Alize Pharma 57
AstraZeneca May Acquire Ariad Pharma 58
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million 60
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 62
Jazz Pharmaceuticals Plc – Key Competitors 65
Jazz Pharmaceuticals Plc – Key Employees 66
Jazz Pharmaceuticals Plc – Locations And Subsidiaries 67
Head Office 67
Other Locations & Subsidiaries 67
Recent Developments 69
Financial Announcements 69
Nov 06, 2018: Jazz Pharmaceuticals announces third quarter 2018 financial results 69
Aug 07, 2018: Jazz Pharmaceuticals announces second quarter 2018 financial results 71
May 08, 2018: Jazz Pharmaceuticals Reports First Quarter 2018 Financial Results 73
Feb 27, 2018: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results 75
Nov 07, 2017: Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results 77
Aug 08, 2017: Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results 78
May 09, 2017: Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results 79
Feb 28, 2017: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results 81
Corporate Communications 83
Dec 04, 2017: Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer 83
Product News 84
08/03/2017: Jazz Pharmaceuticals Announces FDA Approval of Vyxeos Liposome for Injection for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC) 84
08/03/2017: Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update 85
03/19/2018: Clinigen appointed by Jazz Pharmaceuticals to manage Managed Access Program for Vyxeos (CPX-351) outside the United States 86
02/08/2018: National Comprehensive Cancer Network adds Jazz Pharmaceuticals’ Vyxeos (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology 87
Product Approvals 88
Nov 03, 2017: Jazz Pharmaceuticals Submits Vyxeos Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia 88
May 31, 2017: Jazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status 89
Apr 03, 2017: Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia 90
Clinical Trials 91
Nov 01, 2017: Jazz Pharmaceuticals to Present Abstracts on Vyxeos at ASH 2017 Annual Meeting 91
Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients 94
Appendix 95
Methodology 95
About GlobalData 95
Contact Us 95
Disclaimer 95

List of Tables
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Jazz Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
JAZZ Pharma Acquires Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million 16
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 17
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million 19
Arrivo BioVentures Raises USD49 Million in Venture Financing 20
Alize Pharma Raises USD1.9 Million in Venture Financing 21
Alize Pharma Raises USD6.4 Million in Series A Financing 22
Celator Pharma Raises US$39 Million In Venture Financing 23
Celator Pharma Raises USD4.1 Million in Venture Financing 24
Alize Pharma Raises US$4 Million In Venture Financing 25
Jazz Pharma and MD Anderson Cancer Center Enter into Agreement 26
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 27
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 28
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 29
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 30
Jazz Pharma Merges With Azur Pharma In All Stock Transaction 31
Jazz Pharma Enters into License Agreement with XL-protein 33
Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 34
Jazz Pharma Amends Licensing Agreement with Pfenex 35
Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 37
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 38
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 40
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 41
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 43
Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 45
Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 46
TerSera Therapeutics to Acquire Prialt from Jazz Pharma for USD80 Million 47
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 48
Aytu BioScience Acquires ProstaScint from Jazz Pharma 49
Essex Bidco Acquires Assets from Jazz Pharma 50
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 52
Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For US$95 Million 53
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 55
Jazz Pharma Acquires Alize Pharma 57
AstraZeneca May Acquire Ariad Pharma 58
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million 60
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 62
Jazz Pharmaceuticals Plc, Key Competitors 65
Jazz Pharmaceuticals Plc, Key Employees 66
Jazz Pharmaceuticals Plc, Other Locations 67
Jazz Pharmaceuticals Plc, Subsidiaries 67

List of Figures
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Jazz Pharmaceuticals Plc (JAZZ)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Open Text Corporation (OTEX)：企業の財務・戦略的SWOT分析
    Open Text Corporation (OTEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Global Investment House KPSC：企業の戦略的SWOT分析
    Global Investment House KPSC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • FLYHT Aerospace Solutions Ltd.：企業の戦略・SWOT・財務分析
    FLYHT Aerospace Solutions Ltd. - Strategy, SWOT and Corporate Finance Report Summary FLYHT Aerospace Solutions Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Harbor MedTech Inc：医療機器：M&Aディール及び事業提携情報
    Summary Harbor MedTech Inc (Harbor MedTech) is a commercial-stage regenerative medicine company that offers tissue regeneration solutions. The company offers Architect, an extracellular collagen matrix used in managing partial and full thickness wounds. Its collagen wound matrix systems are used in …
  • Cleanaway Waste Management Ltd (CWY)：企業の戦略的SWOT分析
    Cleanaway Waste Management Ltd (CWY) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Offshore Marine Management Limited：企業の戦略的SWOT分析
    Offshore Marine Management Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Al Madina Insurance Co SAOG (AMAT)：企業の財務・戦略的SWOT分析
    Al Madina Insurance Co SAOG (AMAT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • MVV Energie AG (MVV1)：企業の財務・戦略的SWOT分析
    MVV Energie AG (MVV1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Basilea Pharmaceutica Ltd (BSLN)：企業の財務・戦略的SWOT分析
    Summary Basilea Pharmaceutica Ltd (Basilea) is a biopharmaceutical company that develops and markets antibiotics, antifungals and oncology drugs. The company’s products address increasing resistance and non-response to present treatment options for various therapeutic areas such as cancer, bacterial …
  • AxoGen Inc (AXGN)：医療機器：M&Aディール及び事業提携情報
    Summary AxoGen Inc (AxoGen), formerly LecTec Corp is a provider of surgical solutions to measure and monitor nerve functions. The company offers products such as AxoTouch two-point discriminator, AxoGuard nerve connector, Avance nerve graft, AcroVal NSTMS and AxoGuard nerve protector products, among …
  • MAXONS Restorations Inc：企業の戦略的SWOT分析
    MAXONS Restorations Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Burns & McDonnell：企業の戦略・SWOT・財務情報
    Burns & McDonnell - Strategy, SWOT and Corporate Finance Report Summary Burns & McDonnell - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Sumitomo Bakelite Co Ltd (4203)：企業の財務・戦略的SWOT分析
    Sumitomo Bakelite Co Ltd (4203) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • SLM Corp：企業の戦略・SWOT・財務情報
    SLM Corp - Strategy, SWOT and Corporate Finance Report Summary SLM Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Nuo Therapeutics Inc (AURX)：企業の財務・戦略的SWOT分析
    Nuo Therapeutics Inc (AURX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • InBios International Inc：企業の製品パイプライン分析
    Summary InBios International Inc (InBios International) is a medical device company that develops, manufactures and markets medical diagnostic tests for detecting infectious diseases. The company offers products such as assays, ELISA kits, rapid immunoassays, veterinary products, and monoclonal anti …
  • Corcept Therapeutics Inc (CORT)：企業の財務・戦略的SWOT分析
    Corcept Therapeutics Inc (CORT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Bank Muscat：企業の戦略・SWOT・財務分析
    Bank Muscat - Strategy, SWOT and Corporate Finance Report Summary Bank Muscat - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Hansen Technologies Ltd (HSN)：企業の財務・戦略的SWOT分析
    Summary Hansen Technologies Ltd (Hansen Technologies) is a technology company that offers customer care, billing, and meter data management software solutions. The company provides outsourcing services such as facilities management, support center, consulting, host management, business continuity, i …
  • F-Secure Oyj (FSC1V)：企業の財務・戦略的SWOT分析
    F-Secure Oyj (FSC1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆